AML patient series with biological and clinical characteristics
| . | Patient series . | ||||
|---|---|---|---|---|---|
| HOVON . | German . | TCGA . | TARGET . | Beat AML . | |
| Patients, n | 593 | 535 | 128 | 145 | 242 |
| Males/females, n | 306/287 | N.A. | 70/58 | 74/71 | 109/133 |
| Median follow-up, y | 8.34 | 8.61 | 3.25 | 6.78 | 1.27 |
| Age group, n | |||||
| 0-14 y | 0 | 0 | 0 | 114 | 10 |
| 15-39 y | 188 | 93 | 25 | 31 | 36 |
| 40-59 y | 327 | 185 | 41 | 0 | 64 |
| ≥60 y | 78 | 257 | 60 | 0 | 132 |
| N.A. | 0 | 0 | 2 | 0 | 0 |
| WHO category | |||||
| AML with minimal differentiation/without maturation | 161 | N.A. | 41 | N.A. | 6 |
| AML with t(8;21)(q22;q22) | 46 | N.A. | 7 | 21 | 9 |
| AML with inv(16)(p13;q22) | 49 | N.A. | 9 | 28 | 17 |
| AML with biallelic mutations of CEBPA | 28 | N.A. | N.A. | 7 | 17 |
| AML with mutated NPM1 | 183 | N.A. | N.A. | 5 | 64 |
| AML with t(9;11)(p22;q23) | 21 | N.A. | 7 | 36 | 8 |
| AML with inv(3)(q21q26)/t(3;3)(q21;q26) | 15 | N.A. | N.A. | 0 | 4 |
| Acute myelomonocytic leukemia | 112 | N.A. | 18 | N.A. | 13 |
| Acute monoblastic/monocytic leukemia | 139 | N.A. | 13 | N.A. | 11 |
| Pure erythroid leukemia | 9 | N.A. | N.A. | N.A. | 1 |
| AML with myelodysplasia-related changes | N.A. | N.A. | N.A. | N.A. | 45 |
| AML, not otherwise specified | N.A. | N.A. | N.A. | N.A. | 27 |
| Median presenting WBC count (range), ×109/L | N.A. | N.A. | 15 (1-224) | 45.3 (1.3-519) | 24.2 (0.5-427) |
| Median percentage of BM blasts (range) | 73 (0-98) | N.A. | 72 (30-100) | 73 (14-100) | 71 (1-98) |
| ELN cytogenetic risk group, n (%) | |||||
| Favorable | 201 (34) | N.A. | 18 (14) | 60 (41) | 73 (30) |
| Intermediate | 263 (44) | 223 | 76 (59) | 69 (48) | 80 (33) |
| Adverse | 126 (21) | N.A. | 32 (25) | 8 (5.5) | 89 (37) |
| N.A. | 3 (1) | 0 | 2 (2) | 8 (5.5) | 0 |
| HSCT, n | |||||
| Autologous | 95 | N.A. | 4 | N.A. | 0 |
| Allogeneic | 181 | N.A. | 55 | N.A. | 75 |
| WHO performance status, n | |||||
| 0 | 254 | N.A. | N.A. | N.A. | N.A. |
| 1 | 270 | ||||
| 2 | 53 | ||||
| 3 | 12 | ||||
| 4 | 0 | ||||
| N.A. | 4 | ||||
| Gene-expression platform | Affymetrix Human Genome U133 Plus 2.0 Array | Affymetrix Human Genome U133 Plus 2.0, U133A/B Array | RNA sequencing | RNA sequencing | RNA sequencing |
| . | Patient series . | ||||
|---|---|---|---|---|---|
| HOVON . | German . | TCGA . | TARGET . | Beat AML . | |
| Patients, n | 593 | 535 | 128 | 145 | 242 |
| Males/females, n | 306/287 | N.A. | 70/58 | 74/71 | 109/133 |
| Median follow-up, y | 8.34 | 8.61 | 3.25 | 6.78 | 1.27 |
| Age group, n | |||||
| 0-14 y | 0 | 0 | 0 | 114 | 10 |
| 15-39 y | 188 | 93 | 25 | 31 | 36 |
| 40-59 y | 327 | 185 | 41 | 0 | 64 |
| ≥60 y | 78 | 257 | 60 | 0 | 132 |
| N.A. | 0 | 0 | 2 | 0 | 0 |
| WHO category | |||||
| AML with minimal differentiation/without maturation | 161 | N.A. | 41 | N.A. | 6 |
| AML with t(8;21)(q22;q22) | 46 | N.A. | 7 | 21 | 9 |
| AML with inv(16)(p13;q22) | 49 | N.A. | 9 | 28 | 17 |
| AML with biallelic mutations of CEBPA | 28 | N.A. | N.A. | 7 | 17 |
| AML with mutated NPM1 | 183 | N.A. | N.A. | 5 | 64 |
| AML with t(9;11)(p22;q23) | 21 | N.A. | 7 | 36 | 8 |
| AML with inv(3)(q21q26)/t(3;3)(q21;q26) | 15 | N.A. | N.A. | 0 | 4 |
| Acute myelomonocytic leukemia | 112 | N.A. | 18 | N.A. | 13 |
| Acute monoblastic/monocytic leukemia | 139 | N.A. | 13 | N.A. | 11 |
| Pure erythroid leukemia | 9 | N.A. | N.A. | N.A. | 1 |
| AML with myelodysplasia-related changes | N.A. | N.A. | N.A. | N.A. | 45 |
| AML, not otherwise specified | N.A. | N.A. | N.A. | N.A. | 27 |
| Median presenting WBC count (range), ×109/L | N.A. | N.A. | 15 (1-224) | 45.3 (1.3-519) | 24.2 (0.5-427) |
| Median percentage of BM blasts (range) | 73 (0-98) | N.A. | 72 (30-100) | 73 (14-100) | 71 (1-98) |
| ELN cytogenetic risk group, n (%) | |||||
| Favorable | 201 (34) | N.A. | 18 (14) | 60 (41) | 73 (30) |
| Intermediate | 263 (44) | 223 | 76 (59) | 69 (48) | 80 (33) |
| Adverse | 126 (21) | N.A. | 32 (25) | 8 (5.5) | 89 (37) |
| N.A. | 3 (1) | 0 | 2 (2) | 8 (5.5) | 0 |
| HSCT, n | |||||
| Autologous | 95 | N.A. | 4 | N.A. | 0 |
| Allogeneic | 181 | N.A. | 55 | N.A. | 75 |
| WHO performance status, n | |||||
| 0 | 254 | N.A. | N.A. | N.A. | N.A. |
| 1 | 270 | ||||
| 2 | 53 | ||||
| 3 | 12 | ||||
| 4 | 0 | ||||
| N.A. | 4 | ||||
| Gene-expression platform | Affymetrix Human Genome U133 Plus 2.0 Array | Affymetrix Human Genome U133 Plus 2.0, U133A/B Array | RNA sequencing | RNA sequencing | RNA sequencing |
N.A., not available; TARGET, Therapeutically Applicable Research to Generate Effective Treatments; TCGA, The Cancer Genome Atlas; WHO, World Health Organization.